Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Moringa Acquisition CorpMACA,MACAU · Entity 110260 | 10% owner | February 19, 2021 | March 04, 2021 |
| Silexion Therapeutics CorpSLXN · Entity 8506 | Director · 10% owner | August 07, 2025 | January 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Moringa Acquisition Corp
Report date February 19, 2021 · Filed March 04, 2021
Jointly reported with Moringa Sponsor, LP, Moringa Sponsor US L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Units composed of 1 Class A ordinary share & 0.5 warrantsSEC Table I · non-derivative | IndirectBy Moringa Sponsor US L.P. | 352,857 |
Last balance in matching sequence
After 2021-03-03 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2021-02-19 · Purchase · Acquired 325,000 · Balance 325,000 F1: The Class A ordinary shares and warrants comprising the units are expected to begin separate trading on the 90th day following the date of the prospectus for the Issuer's initial public offering, unless the representative of the underwriters for that offering allows earlier separate trading, which would be publicly announced by the Issuer. F2: Moringa Sponsor US L.P. purchased, in a private placement concurrent with the initial closing under the Issuer's initial public offering, 325,000 units, at a purchase price of $10.00 per unit. F3: Moringa Sponsor US L.P. (which purchased the units and also holds the Class A ordinary shares reported herein) is a wholly-owned subsidiary of Moringa Sponsor, LP (those two entities, the "Sponsor Entities"). Mr. Ilan Levin serves as the sole director of, and is the sole equity owner of, the sole general partner of the Sponsor Entities and therefore possesses sole voting and investment authority with respect to the securities reported in this line. The limited partnership interests of Moringa Sponsor, LP are held by various individuals and entities. Mr. Levin disclaims beneficial ownership of the securities reported herein other than to the extent of his indirect pecuniary interest therein. Row 2 · 2021-03-03 · Purchase · Acquired 27,857 · Balance 352,857 F1: The Class A ordinary shares and warrants comprising the units are expected to begin separate trading on the 90th day following the date of the prospectus for the Issuer's initial public offering, unless the representative of the underwriters for that offering allows earlier separate trading, which would be publicly announced by the Issuer. F4: Moringa Sponsor US L.P. purchased, in a private placement concurrent with an additional closing under the Issuer's initial public offering, 27,857 units, at a purchase price of $10.00 per unit. F3: Moringa Sponsor US L.P. (which purchased the units and also holds the Class A ordinary shares reported herein) is a wholly-owned subsidiary of Moringa Sponsor, LP (those two entities, the "Sponsor Entities"). Mr. Ilan Levin serves as the sole director of, and is the sole equity owner of, the sole general partner of the Sponsor Entities and therefore possesses sole voting and investment authority with respect to the securities reported in this line. The limited partnership interests of Moringa Sponsor, LP are held by various individuals and entities. Mr. Levin disclaims beneficial ownership of the securities reported herein other than to the extent of his indirect pecuniary interest therein. |
| Class A ordinary sharesSEC Table I · non-derivative | IndirectBy Moringa Sponsor US L.P. | 2,875,000 |
Reported balance
Holding disclosure · report date 2021-02-19 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 2,875,000 F5: No transaction has been effected by the Reporting Persons with respect to these securities, and they are being included in this Form 4 for informational purposes only. F3: Moringa Sponsor US L.P. (which purchased the units and also holds the Class A ordinary shares reported herein) is a wholly-owned subsidiary of Moringa Sponsor, LP (those two entities, the "Sponsor Entities"). Mr. Ilan Levin serves as the sole director of, and is the sole equity owner of, the sole general partner of the Sponsor Entities and therefore possesses sole voting and investment authority with respect to the securities reported in this line. The limited partnership interests of Moringa Sponsor, LP are held by various individuals and entities. Mr. Levin disclaims beneficial ownership of the securities reported herein other than to the extent of his indirect pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The Class A ordinary shares and warrants comprising the units are expected to begin separate trading on the 90th day following the date of the prospectus for the Issuer's initial public offering, unless the representative of the underwriters for that offering allows earlier separate trading, which would be publicly announced by the Issuer.
F2: Moringa Sponsor US L.P. purchased, in a private placement concurrent with the initial closing under the Issuer's initial public offering, 325,000 units, at a purchase price of $10.00 per unit.
F3: Moringa Sponsor US L.P. (which purchased the units and also holds the Class A ordinary shares reported herein) is a wholly-owned subsidiary of Moringa Sponsor, LP (those two entities, the "Sponsor Entities"). Mr. Ilan Levin serves as the sole director of, and is the sole equity owner of, the sole general partner of the Sponsor Entities and therefore possesses sole voting and investment authority with respect to the securities reported in this line. The limited partnership interests of Moringa Sponsor, LP are held by various individuals and entities. Mr. Levin disclaims beneficial ownership of the securities reported herein other than to the extent of his indirect pecuniary interest therein.
F4: Moringa Sponsor US L.P. purchased, in a private placement concurrent with an additional closing under the Issuer's initial public offering, 27,857 units, at a purchase price of $10.00 per unit.
F5: No transaction has been effected by the Reporting Persons with respect to these securities, and they are being included in this Form 4 for informational purposes only.
Silexion Therapeutics Corp
Report date August 07, 2025 · Filed January 27, 2026
Jointly reported with Moringa Sponsor, LP
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Moringa Sponsor, LP. | 456,970 |
Last balance in matching sequence
After 2025-09-15 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2025-08-07 · Other · Disposed 5,550 · Balance 6,970 F1: The transaction reported in this row was the pro rata distribution, for no consideration, by Moringa Sponsor, LP. to certain of its limited partners, of ordinary shares or warrants (as applicable) of the Issuer in proportion to those limited partners' respective pro rata interests in the equity of Moringa Sponsor, LP. F2: The numbers of ordinary shares reported in this Form 4 reflect a 1-for-9 reverse share split effected by the Issuer on November 29, 2024 and a 1-for-15 reverse share split effected by the Issuer on July 29, 2025. F3: Ilan Levin is the sole equity owner and serves as the sole director of Moringa Partners Ltd., a company that is the sole general partner of Moringa Sponsor, LP. (which holds the subject ordinary shares or warrants, as applicable). As a result of that relationship, Mr. Levin possesses sole voting and investment authority with respect to the subject ordinary shares or warrants. The limited partnership interests of Moringa Sponsor, LP, are held by various individuals and entities. Ilan Levin disclaims beneficial ownership of the subject ordinary shares or warrants (as applicable) except to the extent of his indirect pecuniary interest therein. Row 2 · 2025-09-15 · Grant · Acquired 450,000 · Balance 456,970 F4: The transaction reported in this row was the issuance of 450,000 ordinary shares to Moringa Sponsor, LP. upon conversion of $1,800,000 of the outstanding principal amount under the convertible promissory note, dated August 15, 2024, issued by the Issuer to Moringa Sponsor, LP., which is convertible based on the market price of the ordinary shares or the price at which the Issuer sells ordinary shares in an equity financing from time to time. The conversion price was $4.00 per share and the related issuance was approved by the Issuer's board of directors. The Reporting Persons expressly dispute the validity of the subject issuance and do not concede beneficial ownership of those 450,000 shares. F2: The numbers of ordinary shares reported in this Form 4 reflect a 1-for-9 reverse share split effected by the Issuer on November 29, 2024 and a 1-for-15 reverse share split effected by the Issuer on July 29, 2025. F3: Ilan Levin is the sole equity owner and serves as the sole director of Moringa Partners Ltd., a company that is the sole general partner of Moringa Sponsor, LP. (which holds the subject ordinary shares or warrants, as applicable). As a result of that relationship, Mr. Levin possesses sole voting and investment authority with respect to the subject ordinary shares or warrants. The limited partnership interests of Moringa Sponsor, LP, are held by various individuals and entities. Ilan Levin disclaims beneficial ownership of the subject ordinary shares or warrants (as applicable) except to the extent of his indirect pecuniary interest therein. |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1,552.50 · Expires 2029-08-15 | IndirectBy Moringa Sponsor, LP. | 372 |
Reported balance
After 2025-08-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-08-07 · Other · Disposed 935 · Balance 372 F7: The number of warrants to purchase ordinary shares, and underlying ordinary shares, reported in this row have been adjusted downwards, and the exercise price of those warrants has been adjusted proportionately upwards, to reflect the 1-for-9 reverse share split effected by the Issuer on November 29, 2024 and the 1-for-15 reverse share split effected by the Issuer on July 29, 2025. F1: The transaction reported in this row was the pro rata distribution, for no consideration, by Moringa Sponsor, LP. to certain of its limited partners, of ordinary shares or warrants (as applicable) of the Issuer in proportion to those limited partners' respective pro rata interests in the equity of Moringa Sponsor, LP. F3: Ilan Levin is the sole equity owner and serves as the sole director of Moringa Partners Ltd., a company that is the sole general partner of Moringa Sponsor, LP. (which holds the subject ordinary shares or warrants, as applicable). As a result of that relationship, Mr. Levin possesses sole voting and investment authority with respect to the subject ordinary shares or warrants. The limited partnership interests of Moringa Sponsor, LP, are held by various individuals and entities. Ilan Levin disclaims beneficial ownership of the subject ordinary shares or warrants (as applicable) except to the extent of his indirect pecuniary interest therein. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Greenstar, L.P. | 1,482 |
Reported balance
Holding disclosure · report date 2025-08-07 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,482 F5: There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. F2: The numbers of ordinary shares reported in this Form 4 reflect a 1-for-9 reverse share split effected by the Issuer on November 29, 2024 and a 1-for-15 reverse share split effected by the Issuer on July 29, 2025. F6: Moringa Partners Ltd. serves as the sole general partner of Greenstar, L.P. As a result of Ilan Levin being the sole equity owner and serving as the sole director of Moringa Partners Ltd. (as described in footnote (3) above), Mr. Levin possesses sole voting and investment authority with respect to the subject ordinary shares. The limited partnership interests of Greenstar, L.P. may be held from time to time by various individuals and entities. Mr. Levin disclaims beneficial ownership of the subject ordinary shares except to the extent of his indirect pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported in this row was the pro rata distribution, for no consideration, by Moringa Sponsor, LP. to certain of its limited partners, of ordinary shares or warrants (as applicable) of the Issuer in proportion to those limited partners' respective pro rata interests in the equity of Moringa Sponsor, LP.
F2: The numbers of ordinary shares reported in this Form 4 reflect a 1-for-9 reverse share split effected by the Issuer on November 29, 2024 and a 1-for-15 reverse share split effected by the Issuer on July 29, 2025.
F3: Ilan Levin is the sole equity owner and serves as the sole director of Moringa Partners Ltd., a company that is the sole general partner of Moringa Sponsor, LP. (which holds the subject ordinary shares or warrants, as applicable). As a result of that relationship, Mr. Levin possesses sole voting and investment authority with respect to the subject ordinary shares or warrants. The limited partnership interests of Moringa Sponsor, LP, are held by various individuals and entities. Ilan Levin disclaims beneficial ownership of the subject ordinary shares or warrants (as applicable) except to the extent of his indirect pecuniary interest therein.
F4: The transaction reported in this row was the issuance of 450,000 ordinary shares to Moringa Sponsor, LP. upon conversion of $1,800,000 of the outstanding principal amount under the convertible promissory note, dated August 15, 2024, issued by the Issuer to Moringa Sponsor, LP., which is convertible based on the market price of the ordinary shares or the price at which the Issuer sells ordinary shares in an equity financing from time to time. The conversion price was $4.00 per share and the related issuance was approved by the Issuer's board of directors. The Reporting Persons expressly dispute the validity of the subject issuance and do not concede beneficial ownership of those 450,000 shares.
F5: There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.
F6: Moringa Partners Ltd. serves as the sole general partner of Greenstar, L.P. As a result of Ilan Levin being the sole equity owner and serving as the sole director of Moringa Partners Ltd. (as described in footnote (3) above), Mr. Levin possesses sole voting and investment authority with respect to the subject ordinary shares. The limited partnership interests of Greenstar, L.P. may be held from time to time by various individuals and entities. Mr. Levin disclaims beneficial ownership of the subject ordinary shares except to the extent of his indirect pecuniary interest therein.
F7: The number of warrants to purchase ordinary shares, and underlying ordinary shares, reported in this row have been adjusted downwards, and the exercise price of those warrants has been adjusted proportionately upwards, to reflect the 1-for-9 reverse share split effected by the Issuer on November 29, 2024 and the 1-for-15 reverse share split effected by the Issuer on July 29, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2025 Filed Jan 27, 2026 16:03 UTC | Silexion Therapeutics Corp SLXN · Entity 8506 | GrantOrdinary Shares | 450,000 | $4.00 | $1,800,000.00 |
DisclosureSEC source: 0001178913-26-000228 · zk2634255.xml · nonDerivative · entry 2 Levin Ilan · CIK 0001849189 · Director · 10% owner Moringa Sponsor, LP · CIK 0001849192 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Moringa Sponsor, LP. Disclosed balance after: 456,970 F4 · kind: The transaction reported in this row was the issuance of 450,000 ordinary shares to Moringa Sponsor, LP. upon conversion of $1,800,000 of the outstanding principal amount under the convertible promissory note, dated August 15, 2024, issued by the Issuer to Moringa Sponsor, LP., which is convertible based on the market price of the ordinary shares or the price at which the Issuer sells ordinary shares in an equity financing from time to time. The conversion price was $4.00 per share and the related issuance was approved by the Issuer's board of directors. The Reporting Persons expressly dispute the validity of the subject issuance and do not concede beneficial ownership of those 450,000 shares. F4 · shares: The transaction reported in this row was the issuance of 450,000 ordinary shares to Moringa Sponsor, LP. upon conversion of $1,800,000 of the outstanding principal amount under the convertible promissory note, dated August 15, 2024, issued by the Issuer to Moringa Sponsor, LP., which is convertible based on the market price of the ordinary shares or the price at which the Issuer sells ordinary shares in an equity financing from time to time. The conversion price was $4.00 per share and the related issuance was approved by the Issuer's board of directors. The Reporting Persons expressly dispute the validity of the subject issuance and do not concede beneficial ownership of those 450,000 shares. F2 · balance_after: The numbers of ordinary shares reported in this Form 4 reflect a 1-for-9 reverse share split effected by the Issuer on November 29, 2024 and a 1-for-15 reverse share split effected by the Issuer on July 29, 2025. F3 · ownership.nature: Ilan Levin is the sole equity owner and serves as the sole director of Moringa Partners Ltd., a company that is the sole general partner of Moringa Sponsor, LP. (which holds the subject ordinary shares or warrants, as applicable). As a result of that relationship, Mr. Levin possesses sole voting and investment authority with respect to the subject ordinary shares or warrants. The limited partnership interests of Moringa Sponsor, LP, are held by various individuals and entities. Ilan Levin disclaims beneficial ownership of the subject ordinary shares or warrants (as applicable) except to the extent of his indirect pecuniary interest therein. Read SEC document |
| August 07, 2025 Filed Jan 27, 2026 16:03 UTC | Silexion Therapeutics Corp SLXN · Entity 8506 | OtherWarrant (right to buy) · Derivative | 935 | $0.00 Strike: $1,552.50 | $0.00 |
DisclosureSEC source: 0001178913-26-000228 · zk2634255.xml · derivative · entry 4 Levin Ilan · CIK 0001849189 · Director · 10% owner Moringa Sponsor, LP · CIK 0001849192 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Moringa Sponsor, LP. Disclosed balance after: 372 Underlying: Ordinary Shares · 935 shares Expires 2029-08-15 F7 · derivative.exercise_price: The number of warrants to purchase ordinary shares, and underlying ordinary shares, reported in this row have been adjusted downwards, and the exercise price of those warrants has been adjusted proportionately upwards, to reflect the 1-for-9 reverse share split effected by the Issuer on November 29, 2024 and the 1-for-15 reverse share split effected by the Issuer on July 29, 2025. F1 · kind: The transaction reported in this row was the pro rata distribution, for no consideration, by Moringa Sponsor, LP. to certain of its limited partners, of ordinary shares or warrants (as applicable) of the Issuer in proportion to those limited partners' respective pro rata interests in the equity of Moringa Sponsor, LP. F7 · shares: The number of warrants to purchase ordinary shares, and underlying ordinary shares, reported in this row have been adjusted downwards, and the exercise price of those warrants has been adjusted proportionately upwards, to reflect the 1-for-9 reverse share split effected by the Issuer on November 29, 2024 and the 1-for-15 reverse share split effected by the Issuer on July 29, 2025. F7 · derivative.underlying_shares: The number of warrants to purchase ordinary shares, and underlying ordinary shares, reported in this row have been adjusted downwards, and the exercise price of those warrants has been adjusted proportionately upwards, to reflect the 1-for-9 reverse share split effected by the Issuer on November 29, 2024 and the 1-for-15 reverse share split effected by the Issuer on July 29, 2025. F7 · balance_after: The number of warrants to purchase ordinary shares, and underlying ordinary shares, reported in this row have been adjusted downwards, and the exercise price of those warrants has been adjusted proportionately upwards, to reflect the 1-for-9 reverse share split effected by the Issuer on November 29, 2024 and the 1-for-15 reverse share split effected by the Issuer on July 29, 2025. F3 · ownership.nature: Ilan Levin is the sole equity owner and serves as the sole director of Moringa Partners Ltd., a company that is the sole general partner of Moringa Sponsor, LP. (which holds the subject ordinary shares or warrants, as applicable). As a result of that relationship, Mr. Levin possesses sole voting and investment authority with respect to the subject ordinary shares or warrants. The limited partnership interests of Moringa Sponsor, LP, are held by various individuals and entities. Ilan Levin disclaims beneficial ownership of the subject ordinary shares or warrants (as applicable) except to the extent of his indirect pecuniary interest therein. Read SEC document |
| August 07, 2025 Filed Jan 27, 2026 16:03 UTC | Silexion Therapeutics Corp SLXN · Entity 8506 | OtherOrdinary Shares | 5,550 | $0.00 | $0.00 |
DisclosureSEC source: 0001178913-26-000228 · zk2634255.xml · nonDerivative · entry 1 Levin Ilan · CIK 0001849189 · Director · 10% owner Moringa Sponsor, LP · CIK 0001849192 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Moringa Sponsor, LP. Disclosed balance after: 6,970 F1 · kind: The transaction reported in this row was the pro rata distribution, for no consideration, by Moringa Sponsor, LP. to certain of its limited partners, of ordinary shares or warrants (as applicable) of the Issuer in proportion to those limited partners' respective pro rata interests in the equity of Moringa Sponsor, LP. F2 · shares: The numbers of ordinary shares reported in this Form 4 reflect a 1-for-9 reverse share split effected by the Issuer on November 29, 2024 and a 1-for-15 reverse share split effected by the Issuer on July 29, 2025. F2 · balance_after: The numbers of ordinary shares reported in this Form 4 reflect a 1-for-9 reverse share split effected by the Issuer on November 29, 2024 and a 1-for-15 reverse share split effected by the Issuer on July 29, 2025. F3 · ownership.nature: Ilan Levin is the sole equity owner and serves as the sole director of Moringa Partners Ltd., a company that is the sole general partner of Moringa Sponsor, LP. (which holds the subject ordinary shares or warrants, as applicable). As a result of that relationship, Mr. Levin possesses sole voting and investment authority with respect to the subject ordinary shares or warrants. The limited partnership interests of Moringa Sponsor, LP, are held by various individuals and entities. Ilan Levin disclaims beneficial ownership of the subject ordinary shares or warrants (as applicable) except to the extent of his indirect pecuniary interest therein. Read SEC document |
| March 03, 2021 Filed Mar 4, 2021 15:16 UTC | Moringa Acquisition Corp MACA,MACAU · Entity 110260 | PurchaseUnits composed of 1 Class A ordinary share & 0.5 warrants | 27,857 | $10.00 | $278,570.00 |
DisclosureSEC source: 0001213900-21-013421 · ownership.xml · nonDerivative · entry 2 Moringa Sponsor, LP · CIK 0001849192 · 10% owner Moringa Sponsor US L.P. · CIK 0001849191 · 10% owner Levin Ilan · CIK 0001849189 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Moringa Sponsor US L.P. Disclosed balance after: 352,857 F1 · security: The Class A ordinary shares and warrants comprising the units are expected to begin separate trading on the 90th day following the date of the prospectus for the Issuer's initial public offering, unless the representative of the underwriters for that offering allows earlier separate trading, which would be publicly announced by the Issuer. F4 · kind: Moringa Sponsor US L.P. purchased, in a private placement concurrent with an additional closing under the Issuer's initial public offering, 27,857 units, at a purchase price of $10.00 per unit. F3 · ownership.nature: Moringa Sponsor US L.P. (which purchased the units and also holds the Class A ordinary shares reported herein) is a wholly-owned subsidiary of Moringa Sponsor, LP (those two entities, the "Sponsor Entities"). Mr. Ilan Levin serves as the sole director of, and is the sole equity owner of, the sole general partner of the Sponsor Entities and therefore possesses sole voting and investment authority with respect to the securities reported in this line. The limited partnership interests of Moringa Sponsor, LP are held by various individuals and entities. Mr. Levin disclaims beneficial ownership of the securities reported herein other than to the extent of his indirect pecuniary interest therein. Read SEC document |
| February 19, 2021 Filed Mar 4, 2021 15:16 UTC | Moringa Acquisition Corp MACA,MACAU · Entity 110260 | PurchaseUnits composed of 1 Class A ordinary share & 0.5 warrants | 325,000 | $10.00 | $3,250,000.00 |
DisclosureSEC source: 0001213900-21-013421 · ownership.xml · nonDerivative · entry 1 Moringa Sponsor, LP · CIK 0001849192 · 10% owner Moringa Sponsor US L.P. · CIK 0001849191 · 10% owner Levin Ilan · CIK 0001849189 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Moringa Sponsor US L.P. Disclosed balance after: 325,000 F1 · security: The Class A ordinary shares and warrants comprising the units are expected to begin separate trading on the 90th day following the date of the prospectus for the Issuer's initial public offering, unless the representative of the underwriters for that offering allows earlier separate trading, which would be publicly announced by the Issuer. F2 · kind: Moringa Sponsor US L.P. purchased, in a private placement concurrent with the initial closing under the Issuer's initial public offering, 325,000 units, at a purchase price of $10.00 per unit. F3 · ownership.nature: Moringa Sponsor US L.P. (which purchased the units and also holds the Class A ordinary shares reported herein) is a wholly-owned subsidiary of Moringa Sponsor, LP (those two entities, the "Sponsor Entities"). Mr. Ilan Levin serves as the sole director of, and is the sole equity owner of, the sole general partner of the Sponsor Entities and therefore possesses sole voting and investment authority with respect to the securities reported in this line. The limited partnership interests of Moringa Sponsor, LP are held by various individuals and entities. Mr. Levin disclaims beneficial ownership of the securities reported herein other than to the extent of his indirect pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.